Goldan Keith A.'s Form 4 filing
Syndax Pharmaceuticals IncSNDX · filed Jul 18, 2025
- Accession no.
- 0000950170-25-096948
- Filed
- Jul 18, 2025
- Trade date
- Jul 16, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $12.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Goldan Keith A.CIK 0001495411 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 16, 2025 | Common Stock | SSaleDisposed | −1,296 | $9.29F1 | −$12,039.84 | 92,450 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units.
Referenced by the price of 1 transaction in Table I.